Loading company…
Satiogen Pharmaceuticals develops treatments for type 2 diabetes based on bile acid mechanisms.
Founded in 2007 in California, Satiogen Pharmaceuticals focused on novel targets and metabolic treatments for type 2 diabetes. Its approach, called the Bile Acid Brake, uses bile acid signaling to regulate food intake and post-meal glucose. The company was co-founded by Andrew Young and Bronislava Gedulin. In May 2022, Mirum Pharmaceuticals acquired it from Mesa Verde Venture Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in